Paul Peter Tak

Board Member

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

CADL

Current role

Board Member

2020-01-01–present

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D., FMedSci, Chief Executive Officer	$743,592	—	—	$3,916,028	$396,653	$288,289	$5,344,561
2024	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D, FMedSci, Chief Executive Officer	$688,940	—	—	—	$498,061	$262,221	$1,449,222
2023	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D, FMedSci, Chief Executive Officer	$670,000	—	$176,506	$189,558	$134,000	$314,695	$1,484,759
2022	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D, FMedSci, Chief Executive Officer	$670,000	—	$334,999	$351,043	$259,625	$229,304	$1,844,971
2021	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D, FMedSci,Chief Executive Officer	$545,116	$85,000	—	—	$167,500	$159,184	$956,800
2020	Candel Therapeutics, Inc. (CADL)	M.D., Ph.D., FMedSci, President and Chief Executive Officer	$134,615	$85,000	—	$2,316,446	$90,450	—	$2,626,511

No earnings-call appearances or filed executive changes recorded yet.